The increasing complexity of cancer chemotherapy makes it mandatory that pharmacists be familiar with these highly toxic agents. This column reviews various issues related to the preparation, dispensing, and administration of cancer chemotherapy, both commercially available and investigational.
Get full access to this article
View all access options for this article.
References
1.
LeMaistreC.F., SalehM.N., KunzelT.M.Phase I trial of a ligand fusion-protein (DAB389IL- 2) in lymphomas expressing the receptor for interleukin-2. Blood.1998; 91(2): 399–405.
2.
SalehM.N., LeMaistreC.F., KuzelT.M.Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides. J Am Acad Dermatol.1998; 39: 63–73.
3.
Unpublished data. Anthra Pharmaceuticals, Inc.
4.
GreenbergR.E., BahnsonR.R., WoodD.Initial report on intravesical administration of N-trifluoroacetyldoxorubicin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder. Urology.1997; 49: 471–5.
